S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
S&P 500   0.52 (-8.53%)
DOW   0.52 (-8.53%)
QQQ   270.38 (+0.37%)
AAPL   438.66 (+0.67%)
MSFT   213.29 (-1.50%)
FB   249.83 (-0.85%)
GOOGL   1,473.30 (-0.64%)
AMZN   3,138.83 (+0.87%)
NVDA   449.11 (+1.98%)
CGC   19.32 (+1.36%)
BABA   262.20 (+1.65%)
TSLA   1,487.00 (+0.13%)
MU   51.30 (+1.81%)
GE   6.14 (+0.49%)
AMD   85.04 (+9.49%)
T   30.01 (+1.32%)
F   6.86 (+2.54%)
ACB   10.73 (+2.98%)
GILD   70.88 (-1.18%)
NFLX   509.64 (+2.21%)
DIS   117.29 (+0.81%)
BAC   25.01 (+0.08%)
BA   165.07 (+1.73%)
Log in

NASDAQ:ATRCAtriCure Stock Price, Forecast & News

$41.26
-0.38 (-0.91 %)
(As of 08/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$40.79
Now: $41.26
$42.08
50-Day Range
$40.81
MA: $44.61
$46.91
52-Week Range
$22.57
Now: $41.26
$51.76
Volume357,590 shs
Average Volume440,038 shs
Market Capitalization$1.85 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.74
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. It also provides multifunctional pens that allow surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and linear ablation devices, which enable users to make longer linear lines of ablation. In addition, the company offers cryoICE cryoablation system used to ablate cardiac tissue for the treatment of cardiac arrhythmias; AtriClip system used to occlude the left atrial appendage by mechanically clamping the appendage; and CryoICE CRYO2 cryoablation system to apply cryo-energy to targeted intercostal peripheral nerves in the ribcage and temporarily relieve pain. Further, it provides Lumitip dissector to separate tissues to provide access to key anatomical structures that are targeted for ablation; Fusion Magnetic Retriever System that allows access around anatomical structures; and cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company sells its products through independent distributors and direct sales personnel. The company was founded in 2000 and is headquartered in Mason, Ohio.
Read More
AtriCure logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$230.81 million
Book Value$6.25 per share

Profitability

Net Income$-35,190,000.00

Miscellaneous

Employees620
Market Cap$1.85 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$41.26
-0.38 (-0.91 %)
(As of 08/4/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AtriCure (NASDAQ:ATRC) Frequently Asked Questions

How has AtriCure's stock been impacted by COVID-19 (Coronavirus)?

AtriCure's stock was trading at $35.28 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ATRC shares have increased by 17.0% and is now trading at $41.26.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of AtriCure?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AtriCure
.

When is AtriCure's next earnings date?

AtriCure is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for AtriCure
.

How were AtriCure's earnings last quarter?

AtriCure Inc. (NASDAQ:ATRC) issued its quarterly earnings data on Tuesday, July, 28th. The medical device company reported ($0.38) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.59) by $0.21. The medical device company earned $40.82 million during the quarter, compared to analyst estimates of $36.07 million. AtriCure had a negative net margin of 23.64% and a negative return on equity of 19.55%. AtriCure's quarterly revenue was down 30.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.17) earnings per share.
View AtriCure's earnings history
.

What price target have analysts set for ATRC?

9 brokers have issued 12-month price objectives for AtriCure's shares. Their forecasts range from $30.00 to $60.00. On average, they anticipate AtriCure's share price to reach $48.78 in the next twelve months. This suggests a possible upside of 18.2% from the stock's current price.
View analysts' price targets for AtriCure
.

Has AtriCure been receiving favorable news coverage?

News articles about ATRC stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AtriCure earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned press coverage about the medical device company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
View the latest news about AtriCure
.

Who are some of AtriCure's key competitors?

What other stocks do shareholders of AtriCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include AbbVie (ABBV), Amgen (AMGN), Gilead Sciences (GILD), Enterprise Products Partners (EPD), Abbott Laboratories (ABT), Neurocrine Biosciences (NBIX), Allergan (AGN), CVS Health (CVS), Walt Disney (DIS) and Intel (INTC).

Who are AtriCure's key executives?

AtriCure's management team includes the following people:
  • Mr. Michael H. Carrel, CEO, Pres & Director (Age 48)
  • Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 44)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 53)
  • Mr. Salvatore Privitera, Chief Technology Officer (Age 52)
  • Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 41)

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

Who are AtriCure's major shareholders?

AtriCure's stock is owned by many different institutional and retail investors. Top institutional shareholders include Emerald Advisers LLC (1.30%), Emerald Mutual Fund Advisers Trust (1.19%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.90%), Peregrine Capital Management LLC (0.80%), First Trust Advisors LP (0.13%) and Foundry Partners LLC (0.09%). Company insiders that own AtriCure stock include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves.
View institutional ownership trends for AtriCure
.

Which major investors are selling AtriCure stock?

ATRC stock was sold by a variety of institutional investors in the last quarter, including BNP PARIBAS ASSET MANAGEMENT Holding S.A., Peregrine Capital Management LLC, Dupont Capital Management Corp, Chartwell Investment Partners LLC, Strs Ohio, Foundry Partners LLC, and MAI Capital Management. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, M Andrew Wade, Mark A Collar, and Michael H Carrel.
View insider buying and selling activity for AtriCure
.

Which major investors are buying AtriCure stock?

ATRC stock was acquired by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Mackay Shields LLC, Brinker Capital Inc., First Trust Advisors LP, Envestnet Asset Management Inc., Clear Creek Financial Management LLC, and SG Americas Securities LLC.
View insider buying and selling activity for AtriCure
.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $41.26.

How big of a company is AtriCure?

AtriCure has a market capitalization of $1.85 billion and generates $230.81 million in revenue each year. The medical device company earns $-35,190,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. AtriCure employs 620 workers across the globe.

What is AtriCure's official website?

The official website for AtriCure is www.atricure.com.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.

This page was last updated on 8/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.